Market Context — Why This Technology, Why Now

The global regenerative medicine market is experiencing robust growth, driven by advancements in biomaterials and increasing investment in tissue engineering. Regulatory bodies are increasingly favoring solutions that demonstrate superior efficacy and safety, pushing for innovations that reduce patient recovery times and healthcare expenditures. This technology aligns perfectly with these trends, offering a validated approach to enhance tissue repair and reduce complications, positioning it as a key enabler for next-generation medical treatments amidst intense competition for superior patient outcomes.

Key Competitive Advantages
01

Accelerates tissue regeneration by 1.5 times through rapid host cell infiltration and efficient engraftment.

02

Provides superior mechanical strength and stability, reducing filler detachment risk.

03

Shortens treatment period by an average of 20% and reduces infection risk.

Market Opportunity
Regenerative Medicine and Wound Healing
$16.5B–$17B globally (AI est.)
Demand for chronic wound treatment, including severe trauma, burns, and diabetic ulcers, is increasing, requiring more effective tissue regeneration technologies.
Regenerative medicine product developers Advanced wound care solution providers Medical device manufacturers specializing in biomaterials
Aesthetic Medicine and Plastic Surgery
$350M–$400M domestically (AI est.)
Needs for advanced tissue fillers that combine aesthetic and functional restoration, such as facial reconstruction, breast reconstruction, and skin rejuvenation, are increasing.
Aesthetic medical product companies Plastic surgery device manufacturers Dermal filler developers
Orthopedics and Dentistry
$6.5B–$7B globally (AI est.)
Materials combining biocompatibility and strength are highly anticipated for bone and soft tissue regeneration treatments, including bone defects, cartilage damage, and periodontal tissue regeneration.
Orthopedic implant manufacturers Dental biomaterial companies Tissue engineering firms for bone/cartilage
IP Defensibility — Why Competitors Can't Replicate This
What This Patent Covers

This patent protects a novel tissue regenerative filler material comprising a porous collagen sponge with an internal honeycomb structure and fibrous collagen within its lumens. The claims are robust, having successfully navigated examiner objections with precise amendments and arguments, indicating a strong and clearly defined scope of protection with high technical originality.

Competitive White Space

This patent focuses on the structural composition of the filler. White space exists in integrating specific growth factors or therapeutic agents within the collagen matrix, or developing novel bio-printing techniques for customized filler geometries.

Economic Impact
~$800K/year estimated treatment cost reduction per facility (est.)
estimated ROI · USD · AI analysis
ROI Calculation Logic

This technology could shorten the period until epidermal transplantation by an average of 10 days compared to conventional artificial dermis. Assuming an average daily hospitalization and treatment cost of ~$333 (AI est.), a medical cost reduction of ~$3,350 per patient (AI est.) is expected. Applying this to 240 patients annually could result in an annual treatment cost reduction of ~$800K (AI est.).

Speed to Market
3× faster than in-house development
This technology has completed fundamental research and prototype development at the university, with accumulated data demonstrating its effectiveness. Extensive knowledge regarding the biocompatibility of collagen materials and processing technology for honeycomb structure formation are also established. By leveraging this proven foundational technology, adopting companies can shorten development time by approximately 2.5 years compared to starting from scratch, aiming for early product commercialization and market entry. Focusing on the regulatory approval process could enable rapid establishment of a competitive advantage.
Competitive Positioning

X: Biocompatibility with Host Tissue
Y: Mechanical Stability and Regeneration Efficiency

Business Models & Applications
🧪 Material Supply to Medical Device Manufacturers
This model involves supplying the tissue regenerative filler material as a semi-finished or final product to medical device manufacturers. Stable supply of high-quality collagen composite material could shorten product development cycles and enhance manufacturers' competitiveness.
📝 Business Expansion Through Licensing
This model involves granting manufacturing and sales licenses for this patent to domestic and international medical device manufacturers and pharmaceutical companies. This could secure royalty income while promoting widespread technology adoption and expanding business scale across broad markets.
🤝 Joint Development for Specific Diseases
This model focuses on jointly developing tissue regenerative filler materials specialized for specific intractable diseases (e.g., chronic ulcers, severe scars) with pharmaceutical companies or research institutions. Joint clinical trials could open niche, high-value markets.
Adjacent Application Opportunities
🐾 Animal Healthcare
Advanced Wound Care for Pets
The veterinary sector faces growing demand for advanced regenerative medicine due to increasing chronic diseases and injuries in aging pets. Adapting this technology could significantly improve pet quality of life and reduce owner burden, potentially reducing healing times by ~20% for complex wounds.
🔬 Research & Cell Culture
High-Performance 3D Cell Culture Scaffolds
Demand for 3D cell culture technologies that mimic in vivo environments is rising in regenerative medicine research and drug screening. This technology's composite structure could serve as a high-performance scaffold, potentially enhancing cell proliferation and differentiation rates by over 50% for complex tissue models.
💄 Aesthetics & Anti-Aging
Collagen-Based Dermal Regeneration Fillers
In aesthetics, collagen supplementation is crucial for restoring skin elasticity and firmness. Leveraging this technology's superior cell engraftment and tissue regeneration capabilities, it could be applied as a highly effective dermal filler or cosmetic material, potentially improving skin regeneration by 1.5 times.
Integration Roadmap — Estimated 36-Month Deployment
Phase 1: Technology Evaluation & Prototype Optimization
Duration: 6 months
Conduct detailed evaluation of the technology's foundational data and design/optimize prototypes to align with the adopting company's existing technologies and product portfolio.
Phase 2: Pre-clinical Trials & Clinical Study Preparation
Duration: 12 months
Perform pre-clinical trials (e.g., animal studies) using optimized prototypes to confirm safety and efficacy, and develop a clinical study plan for regulatory approval.
Phase 3: Regulatory Approval & Mass Production Preparation
Duration: 18 months
Proceed with regulatory approval applications in parallel with collecting clinical trial data, while establishing manufacturing processes, building mass production systems, and implementing quality control.
Technical Feasibility
This technology's main component is collagen, benefiting from extensive knowledge in biocompatible materials. Forming the porous collagen sponge's honeycomb structure is achievable by applying existing freeze-drying or molding manufacturing techniques, and fibrous collagen filling can be handled with established methods. This suggests a relatively low barrier to integration into existing medical material manufacturing facilities and processing lines, indicating high technical feasibility to establish production without significant new capital investment.
Success Scenario
If an adopting company deploys this technology in clinical settings, it could potentially shorten tissue regeneration time by an average of 20% for patients with severe burns or diabetic ulcers. This is estimated to improve patient quality of life, enhance hospital bed turnover, and achieve an annual treatment cost reduction of approximately ~$800K (AI est.). Reduced infection risk could also alleviate the burden on healthcare providers, contributing to the establishment of a sustainable healthcare delivery system.
Patent Record
APPLICATION NO.
特願2020-162634
REGISTRATION NO.
7667541
FILING DATE
2020/09/28
GRANT DATE
2025/04/15
EXPIRATION DATE
2040/09/28
PATENT HOLDER
学校法人東海大学
Examination History
2023年09月26日
出願審査請求書
2024年08月27日
拒絶理由通知書
2024年12月25日
手続補正書（自発・内容）
2024年12月25日
意見書
2025年03月11日
特許査定